Aspira Women's Health Files 8-K with Material Agreement

Ticker: AWHL · Form: 8-K · Filed: 2024-07-31T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, equity-sale, financials

TL;DR

Aspira Women's Health signed a big deal, sold some stock, and filed financials. Details TBD.

AI Summary

On July 31, 2024, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this excerpt.

Why It Matters

This filing indicates significant corporate activity, potentially involving new financing, partnerships, or strategic changes that could impact the company's future operations and stock value.

Risk Assessment

Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks if not managed properly.

Key Players & Entities

Aspira Women's Health Inc. (company) — Registrant
July 31, 2024 (date) — Date of earliest event reported

FAQ

What is the nature of the material definitive agreement entered into by Aspira Women's Health Inc. on July 31, 2024?

The provided excerpt does not specify the details of the material definitive agreement.

What type of equity securities were sold in the unregistered sales reported by Aspira Women's Health Inc.?

The excerpt mentions unregistered sales of equity securities but does not provide specific details about the type of securities.

What are the key financial highlights or changes reported in the financial statements and exhibits filed on July 31, 2024?

The excerpt indicates that financial statements and exhibits were filed, but it does not contain any specific financial data or highlights.

Has Aspira Women's Health Inc. undergone any name changes recently?

The filing lists former company names including VERMILLION, INC. (name change date 20070824), CIPHERGEN BIOSYSTEMS INC (name change date 20000316), and ABIOTIC SYSTEMS (name change date 19950407), but does not indicate a recent name change for Aspira Women's Health Inc. itself.

What is the business address and phone number for Aspira Women's Health Inc.?

The business address is 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738, and the business phone number is 512-519-0400.

From the Filing

0000950170-24-088246.txt : 20240731 0000950170-24-088246.hdr.sgml : 20240731 20240731075756 ACCESSION NUMBER: 0000950170-24-088246 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240731 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240731 DATE AS OF CHANGE: 20240731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241159927 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 awh-20240731.htm 8-K 8-K false 0000926617 0000926617 2024-07-31 2024-07-31   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024     Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           12117 Bee Caves Road Building III Suite 100   Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2024, Aspira Women's Health Inc. (the "Company") entered into a warrant inducement agreement (the “ Warrant Inducement Agreement ”) with the holder (the “Holder”) of (i) a warrant to purchase 311,111 shares of common stock of the Company "the "Comm